---
figid: PMC3092522__nihms289124f2
figtitle: 'HER2-amplified breast cancer: mechanisms of trastuzumab resistance and
  novel targeted therapies'
organisms:
- Homo sapiens
- Mus musculus
- Diaporthe sclerotioides
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
- Danio rerio
pmcid: PMC3092522
filename: nihms289124f2.jpg
figlink: /pmc/articles/PMC3092522/figure/F2/
number: F2
caption: (A) Lapatinib is a dual EGF receptor (EGFR)/HER2 tyrosine kinase inhibitor
  approved for use in trastuzumab-refractory patients. Neratinib is an irreversible
  tyrosine kinase inhibitor of EGFR/HER2. (B) Pertuzumab, a monoclonal antibody to
  HER2, binds to HER2 at a distinct epitope from where trastuzumab binds and prevents
  ligand-induced heterodimerization with HER3. Dysregulated activation of the PI3K–AKT–mTOR
  pathway can mediate trastuzumab resistance, and molecular therapies aimed at directly
  inhibiting PI3K, AKT and mTOR are therefore in development. (C) HSP90 inhibitors
  promote HER2 degradation by blocking the activity of HSP90, a chaperone protein
  that protects HER2 from proteasomal degradation. (D) TDM-1, the antibody–drug conjugate
  of trastuzumab and maytansine, allows for delivery of a potent microtubule inhibitor
  selectively into HER2-overexpressing cells.
papertitle: 'HER2-amplified breast cancer: mechanisms of trastuzumab resistance and
  novel targeted therapies.'
reftext: Devika Gajria, et al. Expert Rev Anticancer Ther. ;11(2):263-275.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9787785
figid_alias: PMC3092522__F2
figtype: Figure
redirect_from: /figures/PMC3092522__F2
ndex: 206ed19c-debd-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3092522__nihms289124f2.html
  '@type': Dataset
  description: (A) Lapatinib is a dual EGF receptor (EGFR)/HER2 tyrosine kinase inhibitor
    approved for use in trastuzumab-refractory patients. Neratinib is an irreversible
    tyrosine kinase inhibitor of EGFR/HER2. (B) Pertuzumab, a monoclonal antibody
    to HER2, binds to HER2 at a distinct epitope from where trastuzumab binds and
    prevents ligand-induced heterodimerization with HER3. Dysregulated activation
    of the PI3K–AKT–mTOR pathway can mediate trastuzumab resistance, and molecular
    therapies aimed at directly inhibiting PI3K, AKT and mTOR are therefore in development.
    (C) HSP90 inhibitors promote HER2 degradation by blocking the activity of HSP90,
    a chaperone protein that protects HER2 from proteasomal degradation. (D) TDM-1,
    the antibody–drug conjugate of trastuzumab and maytansine, allows for delivery
    of a potent microtubule inhibitor selectively into HER2-overexpressing cells.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Erbb2
  - Erbb3
  - Hsp90ab1
  - Hsp90aa1
  - Hsp84-2
  - Hsp84-3
  - Hsp86-ps2
  - Hsp86-ps1
  - Pik3r1
  - Akt1
  - Mtor
  - Rev3l
  - DMPK
  - IGHD1-7
  - ERBB2
  - ERBB3
  - HSP90AA1
  - HSP90B1
  - TRAP1
  - HSP90AB1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - mnb
  - Lam
  - wg
  - mAChR-A
  - Gld2
  - Pdp1
  - Hex-A
  - tal-1A
  - sbRNA:1
  - Hsp83
  - Gp93
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Tor
  - Rev
  - her2
  - her3
  - hsp90aa1.1
  - mtor
  - Temsirolimus
  - Neratinib
  - BEZ235
---
